Mechelen, Belgium; 9 February 2015 - Galapagos NV (Euronext: GLPG) received a transparency notification from BNP Paribas.
Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 5 February 2015 from BNP Paribas Investment Partners SA, BNP Paribas Asset Management SAS, BNP Paribas Investment Partners Belgium SA, BNP Paribas Investment Partners UK Ltd. and CamGestion SA. BNP Paribas notified that on 30 January 2015, these entities under their control held 1,538,622 shares, representing 5.08% of the current 30,299,129 outstanding Galapagos shares. This is the first transparency notice Galapagos received from BNP Paribas.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn’s disease. GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com
Help employers find you! Check out all the jobs and post your resume.
